Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 1651 AL 1665

Parkinson's disease, parkinsonism, and traumatic brain injury

Wong JC, Hazrati LN.

Crit Rev Clin Lab Sci. 2013 Jul-Oct;50(4-5):103-6. doi: 10.3109/10408363.2013.844678.

What are people with Parkinson's disease really impaired on when it comes to making decisions? A meta-analysis of the evidence

Ryterska A, Jahanshahi M, Osman M.

Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2836-46. doi: 10.1016/j.neubiorev.2013.10.005. Epub 2013 Oct 21.

Juvenile parkinsonism as an initial manifestation of gliomatosis cerebri

Jang W, Ha SH, Khang SK, Kim J, Kim SH, Kim HJ.

J Neurol. 2013 Dec;260(12):3161-3. doi: 10.1007/s00415-013-7162-1. Epub 2013 Oct 25.

Tai chi chuan in medicine and health promotion

Lan C, Chen SY, Lai JS, Wong AM.

Evid Based Complement Alternat Med. 2013;2013:502131. doi: 10.1155/2013/502131. Epub 2013 Sep 12.

Vitamin D: preventive and therapeutic potential in Parkinson's disease

Liu Y, Li YW, Tang YL, Liu X, Jiang JH, Li QG, Yuan JY.

Curr Drug Metab. 2013 Nov;14(9):989-93. doi: 10.2174/1389200211314090005.

Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease

Grandas F.

Expert Rev Neurother. 2013 Dec;13(12):1343-53. doi: 10.1586/14737175.2013.839235. Epub 2013 Oct 25.

Early identification and treatment of communication and swallowing deficits in Parkinson disease

Ciucci MR, Grant LM, Rajamanickam ES, Hilby BL, Blue KV, Jones CA, Kelm-Nelson CA.

Semin Speech Lang. 2013 Aug;34(3):185-202. doi: 10.1055/s-0033-1358367. Epub 2013 Oct 28.

Causes and consequences of falls in Parkinson disease patients in a prospective study

Rudzińska M, Bukowczan S, Stożek J, Zajdel K, Mirek E, Chwała W, Wójcik-Pędziwiatr M, Banaszkiewicz K, Szczudlik A.

Neurol Neurochir Pol. 2013 Sep-Oct;47(5):423-30. doi: 10.5114/ninp.2013.38222.

The incidence and risk factors of falls in Parkinson disease: prospective study

Rudzińska M, Bukowczan S, Stożek J, Zajdel K, Mirek E, Chwała W, Wójcik-Pędziwiatr M, Banaszkiewicz K, Szczudlik A.

Neurol Neurochir Pol. 2013 Sep-Oct;47(5):431-7. doi: 10.5114/ninp.2013.38223.

[Apomorphine in advanced Parkinson disease]

Bogucki A.

Neurol Neurochir Pol. 2013 Sep-Oct;47(5):476-83. doi: 10.5114/ninp.2013.38227.

Darkening of white hair following levodopa therapy in a patient with Parkinson's disease

Komagamine T, Suzuki K, Hirata K.

Mov Disord. 2013 Oct;28(12):1643. doi: 10.1002/mds.25696.

Beyond here be dragons: SIBO in Parkinson's disease

Pfeiffer R.

Mov Disord. 2013 Nov;28(13):1764-5. doi: 10.1002/mds.25705. Epub 2013 Oct 24.

Physiological and pathological significance of dynamin-related protein 1 (drp1)-dependent mitochondrial fission in the nervous system

Cho B, Choi SY, Cho HM, Kim HJ, Sun W.

Exp Neurobiol. 2013 Sep;22(3):149-57. doi: 10.5607/en.2013.22.3.149. Epub 2013 Sep 30.

Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy

Youdim MB, Oh YJ.

Exp Neurobiol. 2013 Sep;22(3):167-72. doi: 10.5607/en.2013.22.3.167. Epub 2013 Sep 30.

Role of movement in long-term basal ganglia changes: implications for abnormal motor responses

Simola N, Morelli M, Frazzitta G, Frau L.

Front Comput Neurosci. 2013 Oct 23;7:142. doi: 10.3389/fncom.2013.00142.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias